Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Synthetic aminoindanes: a summary of existing knowledge

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F17%3A43919035" target="_blank" >RIV/00023752:_____/17:43919035 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00216208:11120/17:43915969

  • Výsledek na webu

    <a href="https://www.frontiersin.org/articles/10.3389/fpsyt.2017.00236/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fpsyt.2017.00236/full</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3389/fpsyt.2017.00236" target="_blank" >10.3389/fpsyt.2017.00236</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Synthetic aminoindanes: a summary of existing knowledge

  • Popis výsledku v původním jazyce

    Objectives: Aminoindanes (“bath salts”, a class of novel psychoactive substances, NPSs) increased rapidly in popularity on the recreational drug market, particularly after mephedrone and other synthetic cathinones were banned in the UK in 2010. Novel aminoindanes continue to emerge, but relatively little is known about their effects and risks. Their history, chemistry, pharmacology, behavioural effects, pharmacokinetics and toxicity are reviewed in this paper. Methods: Scientific literature was searched on ISI Web of Knowledge: Web of Science (WoS) during June and July 2017, using English language terms: aminoindane, MDAI, 5,6-methylenedioxy-2-aminoindane, 5-IAI, 5-Iodo-2-aminoindane, 2-aminoindane, MDMAI, 5,6-Methylenedioxy-N-methyl-2-aminoindane, MMAI, 5-Methoxy-6-methyl-2-aminoindane. WoS was selected as it searches several databases simultaneously and has quality criteria for inclusion. For typical use and effects Erowid, PsychonautWiki, Bluelight and Drugs-Forum were searched; for legal status and epidemiology, the European Information System and Database on New Drugs (EDND) was used. Results: Aminoindanes were first synthesized for medical use as e.g., as anti-Parkinsonian drugs and later as a potential compound facilitating psychotherapy, however they are now widely substituted for ecstasy. Their mechanisms of action (primarily via serotonin), mean that they may pose a significant risk of serotonin syndrome at high doses, or when combined with other drugs. Fatally toxic effects have been observed both in the laboratory in animal studies and in clinic, where aminoindanes-related deaths have been reported. Conclusion: Greater knowledge about aminoindanes is urgently required to decrease risks of fatal intoxication, and appropriate legislation is needed to protect public health without impeding research.

  • Název v anglickém jazyce

    Synthetic aminoindanes: a summary of existing knowledge

  • Popis výsledku anglicky

    Objectives: Aminoindanes (“bath salts”, a class of novel psychoactive substances, NPSs) increased rapidly in popularity on the recreational drug market, particularly after mephedrone and other synthetic cathinones were banned in the UK in 2010. Novel aminoindanes continue to emerge, but relatively little is known about their effects and risks. Their history, chemistry, pharmacology, behavioural effects, pharmacokinetics and toxicity are reviewed in this paper. Methods: Scientific literature was searched on ISI Web of Knowledge: Web of Science (WoS) during June and July 2017, using English language terms: aminoindane, MDAI, 5,6-methylenedioxy-2-aminoindane, 5-IAI, 5-Iodo-2-aminoindane, 2-aminoindane, MDMAI, 5,6-Methylenedioxy-N-methyl-2-aminoindane, MMAI, 5-Methoxy-6-methyl-2-aminoindane. WoS was selected as it searches several databases simultaneously and has quality criteria for inclusion. For typical use and effects Erowid, PsychonautWiki, Bluelight and Drugs-Forum were searched; for legal status and epidemiology, the European Information System and Database on New Drugs (EDND) was used. Results: Aminoindanes were first synthesized for medical use as e.g., as anti-Parkinsonian drugs and later as a potential compound facilitating psychotherapy, however they are now widely substituted for ecstasy. Their mechanisms of action (primarily via serotonin), mean that they may pose a significant risk of serotonin syndrome at high doses, or when combined with other drugs. Fatally toxic effects have been observed both in the laboratory in animal studies and in clinic, where aminoindanes-related deaths have been reported. Conclusion: Greater knowledge about aminoindanes is urgently required to decrease risks of fatal intoxication, and appropriate legislation is needed to protect public health without impeding research.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30215 - Psychiatry

Návaznosti výsledku

  • Projekt

    <a href="/cs/project/LO1611" target="_blank" >LO1611: Udržitelnost pro Národní ústav duševního zdraví</a><br>

  • Návaznosti

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Ostatní

  • Rok uplatnění

    2017

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Frontiers in Psychiatry

  • ISSN

    1664-0640

  • e-ISSN

  • Svazek periodika

    8

  • Číslo periodika v rámci svazku

    November

  • Stát vydavatele periodika

    CH - Švýcarská konfederace

  • Počet stran výsledku

    7

  • Strana od-do

    "Article Number: 236"

  • Kód UT WoS článku

    000415593400001

  • EID výsledku v databázi Scopus

    2-s2.0-85034572487